22 November 2021 – Pear Therapeutics today announced that it has received breakthrough device designation from the U.S. FDA for its reSET-A PDT product candidate designed for the treatment of alcohol use disorder.
reSET-A potentially expands Pear’s addiction franchise, which includes FDA authorised products to treat substance use disorder and opioid use disorder.